Amgen (AMGN): FY25 Q3 earnings call, Nov 4, 2025
No Kalshi or Polymarket word markets were listed for Amgen’s Nov 4, 2025 earnings call (FY25 Q3). The transcript is searchable below (quotes of at most 25 words).
UpdatedTranscript
quotes of at most 25 wordsSpeaker-labelled transcript · Source and credits · Used to count words; quotes of at most 25 words.
2 matches for “Eosinophilic”; 2 quoted, at least 25 words apart.
…of patients with severe uncontrolled asthma. This reinforces TEZSPIRE's proven efficacy in eosinophilic disease. Importantly, in this registrational trial, TEZSPIRE demonstrated a reduction in the…
…or equal to 150 cells per microliter. Our Phase III study in eosinophilic esophagitis continues to mature. By targeting thymic stromal lymphopoietin or TSLP at…
Agents: this page as TSV at /api/v1/appearances/amgen:2025-11-04:earnings_call · words: /api/v1/brief?appearance=amgen:2025-11-04:earnings_call · columnar JSON in #parrot-data · llms.txt · MCP